ModifiedColorado Rocky Mountain Health PlansPolicy CS079.T

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

Governs coverage and medical necessity criteria for minimally invasive endoscopic and laparoscopic procedures used to treat upper gastrointestinal conditions (e.g., GERD, achalasia, gastroparesis) for Colorado Rocky Mountain Health Plans members.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

Policy CodePolicy CS079.T

Change TypeMaterial and non-material updates (GES addedCPT codes expanded)

Effective DateApr 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and submit objective documentation of refractory disease and prior therapies when requesting device‑based or procedural interventions (e.g., GES, POEM, MSA/TIF).

SourceLink

POLICY UPDATE CHANGES

Title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases' to the current title.

Removed content/language pertaining to the state of Louisiana.

Added language indicating gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis.

Added CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 to applicable codes.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect most current information.

7CPT codes added

83%POEM 2‑yr success

70%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

G-POEM 1‑yr success

75%GES symptom improvement (case series)

7TOC parts in full policy

Coverage Criteria and Policy Stances

Coverage stances by procedure/indication

GES for gastroparesis: Gastric electrical stimulation (GES) therapy is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

Refer to FDA/HDE labeling for Enterra device per policy.

Surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for treating refractory gastroparesis that has failed other therapies, or chronic intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology.

POEM for achalasia/ diffuse esophageal spasm: Per oral endoscopic myotomy (POEM) is proven and medically necessary for treating individuals with achalasia or diffuse esophageal spasm.

POEM is unproven for other indications.

POEM other indications: Per oral endoscopic myotomy (POEM) is unproven and not medically necessary for all other indications (e.g., Zenker's diverticula) due to insufficient evidence of efficacy.

G-POEM for gastroparesis: Gastric per oral endoscopic myotomy (G-POEM) is unproven and not medically necessary for the treatment of gastroparesis.

Endoscopic and implant therapies for GERD: The following are unproven and not medically necessary for treating GERD due to insufficient evidence of efficacy: endoscopic therapies; injection or implantation techniques; LINX Reflux Management System.

Endoluminal therapy with GERDx is investigational and not medically necessary as it lacks FDA approval.

Procedural coverage considerations

Coverage considerations summarized from guideline recommendations and comparative evidence:

GES consideration: GES may be considered for medically refractory diabetic or idiopathic gastroparesis (humanitarian use device), particularly when standard therapies have failed and symptoms are refractory.prior failed medical therapy

Based on ACG, AGA, and NICE guidance and case-series evidence.

Pyloric interventions: Pyloroplasty and other pyloric interventions have evidence of symptom improvement and may be preferred as first-line surgical therapy for refractory gastroparesis in some reviews.failed medical therapy

Systematic reviews reported greater symptomatic relief with pyloric interventions compared to GES.

POEM for achalasia: POEM is an effective treatment for achalasia (types I–III), non-inferior to laparoscopic Heller myotomy for symptom control but associated with increased reflux risk; may be preferred for type III achalasia.

Coverage considerations for Z-POEM, G-POEM, and Stretta

Coverage stance and considerations based on current evidence summaries

Z-POEM coverage considerations: Z-POEM may be considered a feasible alternative to flexible endoscopic septotomy in expert centers given observational data showing similar procedural times and adverse event rates and potentially higher clinical success, but evidence is limited by retrospective designs, single-center data, variable definitions of success, and need for prospective long-term comparative studies.evidence quality: low-moderate

Refer to expert-center performance and need for prospective data.

G-POEM coverage considerations: G-POEM shows promise with observational meta-analyses reporting ~70% 1-year clinical success and small RCT evidence demonstrating benefit for severe refractory gastroparesis; however, evidence quality is low to very low, long-term durability and patient selection remain uncertain, and serious adverse events have been reported, so coverage should be limited to patients meeting strict refractory criteria in experienced centers or within research protocols.GCSI > 2.3 or severe refractory gastroparesis; prior therapy failure

Consider prior authorization and requirement for objective baseline measures (e.g., GCSI, gastric emptying study).

General clinical criteria (informational)

Coverage considerations informed by the evidence summarized in this section:

Evidence considerations: Procedures may be considered when (1) patient has chronic GERD with persistent symptoms despite optimized PPI therapy or is PPI-dependent; (2) objective testing (pH monitoring, DeMeester score, endoscopy, manometry as appropriate) supports the diagnosis where reported by studies; and (3) device-specific evidence, contraindications, and risks have been reviewed, noting variable quality and durability of evidence across devices.

Derived from multiple device and trial summaries recommending appropriate selection and longer-term RCTs to confirm benefits.

Reported trial inclusion characteristics

Evidence-based candidate characteristics reported in clinical studies

TIF candidate criteria (as used in trials): Adults with chronic GERD refractory to PPI therapy, absent or small hiatal hernia (often ≤2 cm in key RCTs), and abnormal esophageal acid exposure; many trials required daily PPI use for >6 months prior to procedure.

Derived from TEMPO and other TIF trials.

MSA/LINX candidate criteria (as used in trials): Adults with moderate to severe regurgitation or refractory GERD, prior PPI therapy, hiatal hernia typically <3 cm, BMI <35 kg/m2, abnormal pH testing (DeMeester) and absence of Barrett's esophagus or LA grade C/D esophagitis in many studies.

Derived from randomized trials and cohort studies.

Initial therapy / Procedure selection

Covered when ALL of the following are met (as supported by trial data and guideline statements):

MSA candidate criteria

Diagnostic confirmation: Pre-procedure diagnostic assessment including GERD-HRQL questionnaire, upper endoscopy, ambulatory pH monitoring (DeMeester), barium swallow, and esophageal manometry as performed in cohorts/trials.

Endoscopic anti-reflux (TIF/EsophyX/MUSE/Stretta) candidate: Patient has troublesome regurgitation or heartburn, is responsive to pharmacologic therapy or seeks alternatives to lifelong PPI, and does not have severe reflux esophagitis or a large hiatal hernia (>2–3 cm depending on device/trial), with objective testing supporting GERD when available.

Supported by ACG/ASGE conditional recommendations and device-specific study criteria.

POEM / G-POEM candidate: POEM is indicated for achalasia (particularly type III) and should be performed by experienced operators at high-volume centers; G-POEM may be considered for severe, refractory gastroparesis after failure of medical therapy and when objective baseline measures (e.g., GCSI >2.3, gastric emptying study) are documented.

Complications and revision

Consider device removal or not covered when ANY of the following adverse outcomes occur:

Device explant considerations: Device removal or explantation may be required or considered not covered for persistent dysphagia, device erosion, continued reflux or regurgitation despite device therapy, or other device-related complications; reported device removal rates vary (e.g., MSA removal rates reported ~2.7% pooled to 9.2% in some cohorts).

Causes for removal commonly include dysphagia, erosion, and continued reflux.

Updated Coverage Rationale (GES)

Policy updates and coverage stance statements (as recorded in Policy History):

GES coverage update: Gastric electrical stimulation (GES) therapy was added to the Coverage Rationale and is indicated as proven and medically necessary for treating refractory gastroparesis per the policy update.

Full clinical details and operational criteria are described elsewhere in the policy.

Endoluminal therapies for gastroesophageal reflux disease (GERD) such as the GERDx™ system are considered investigational and not medically necessary because they lack U.S. Food and Drug Administration approval and the evidence does not establish durable, clinically meaningful benefit. The policy explicitly lists endoscopic therapies, injection/implantation techniques, and the LINX Reflux Management System among interventions regarded as unproven and not medically necessary for GERD due to insufficient evidence of efficacy.

Descriptions of endoscopic techniques (e.g., GERDx, EsophyX/TIF, MUSE) and injection/implantation approaches (e.g., PMMA/Plexiglas®, Durasphere®) are provided for context, but the policy conclusion is that these endoluminal or implantable approaches remain investigational when used for GERD, and providers should rely on FDA labeling and established surgical options when determining appropriate therapy.

The evidence is insufficient to support use of gastric electrical stimulation (GES) or Z‑POEM outside of clearly defined, medically refractory symptomatic disease or indications for which long‑term effectiveness and durability have been demonstrated. GES (Enterra) has supportive cohort data for refractory diabetic and idiopathic gastroparesis but limitations of single‑center series and lack of long‑term randomized comparisons mean its use should align with FDA/HDE labeling and documented refractory status.

Z‑POEM for Zenker's diverticulum has observational data suggesting comparable short‑term symptom resolution versus flexible endoscopic septotomy, but the literature lacks high‑quality, long‑term comparative studies; therefore Z‑POEM is not supported for broader indications beyond expert‑center, selected use and further research is required.

Endoscopic therapies for GERD, including radiofrequency energy treatment (Stretta), are considered unproven and not medically necessary because the body of evidence is limited, heterogeneous, and generally low quality. Systematic reviews and evidence assessments note small sample sizes, single‑center designs, short follow‑up, and inconsistent outcome measures across studies.

Importantly, at least one well‑conducted randomized, double‑blind, sham‑controlled trial did not demonstrate a significant benefit of Stretta over sham at 24 and 48 weeks, highlighting the uncertainty of its efficacy versus placebo or standard therapies and supporting the policy position that such endoscopic anti‑reflux procedures remain experimental or only selectively considered with robust supporting documentation.

Many minimally invasive endoscopic procedures lack high‑quality evidence demonstrating long‑term control of GERD or durable symptom relief across all patient populations. Studies of endoscopic plication/suturing, polymer injection, and other techniques frequently show early symptomatic improvement with progressive loss of effect over time and are limited by nonrandomized designs and short follow‑up.

Consequently, patients who do not have documented objective testing (for example, ambulatory pH monitoring, DeMeester score, endoscopic assessment of hiatal hernia or esophagitis) or who have not had an adequate trial of medical therapy (optimized PPI use) may be excluded from consideration for these procedures given the lack of consistent long‑term evidence.

Randomized trials and device studies of magnetic sphincter augmentation (MSA/LINX) commonly excluded patients with a hiatal hernia ≥ 3 cm, those with Barrett's esophagus, or with Los Angeles grade C/D esophagitis. These trial‑based inclusion criteria inform candidate selection and mean that MSA evidence may not generalize to patients with larger hernias or severe esophagitis.

Guideline recommendations and trial protocols therefore typically restrict MSA candidacy to patients without large hiatal hernias and without advanced mucosal disease; documentation of hiatal hernia size and endoscopic findings is expected when evaluating suitability for MSA/LINX.

Per the FDA Humanitarian Device Exemption labeling for the Enterra Therapy System, the device should not be used in patients with gastric obstruction or pseudo‑obstruction, prior gastric resection, prior fundoplication, eating disorders, history of seizures, primary swallowing disorders, chemical dependency, or psychogenic vomiting. These contraindications should be reviewed prior to consideration of implantation.

Providers should align patient selection for Enterra with the device labeling and the policy's coverage rationale for GES, ensuring exclusion criteria listed by the FDA are respected in any coverage determination.

The policy was administratively updated to remove language pertaining specifically to Louisiana; no other state‑specific exclusions are documented in the cited sections. Operational and title changes were made during the revision that broadened the policy scope and updated supporting sections.

Per‑oral endoscopic myotomy (POEM) is considered proven and medically necessary for treatment of achalasia and diffuse esophageal spasm, but POEM for other indications (for example, Zenker's diverticulum) is unproven and not medically necessary. Gastric POEM (G‑POEM) for gastroparesis is explicitly listed as unproven and not medically necessary in this policy due to insufficient evidence for that indication.

The document summarizes multiple evidence assessments indicating that G‑POEM shows promise in observational series and small randomized trials but overall evidence quality is low and long‑term effectiveness, safety, and patient selection criteria remain uncertain.

Procedures submitted without documentation that the condition was medically refractory or that appropriate prior therapies were attempted risk being considered not medically necessary. For example, GES and G‑POEM in gastroparesis and many endoscopic GERD procedures were studied in patients with prior failed medical therapy; absence of documentation of such failure or objective testing increases the likelihood of denial.

Prior authorization and review should include records demonstrating prior conservative management (dietary measures, prokinetic and antiemetic trials for gastroparesis; optimized PPI therapy and objective reflux testing for GERD) to support procedural indications.

The Stretta radiofrequency procedure for GERD is not supported by high‑quality, consistent evidence; in a double‑blind, sham‑controlled randomized trial (Zerbib et al.) Stretta did not show superiority to sham at 24 and 48 weeks. Systematic reviews and health technology assessments conclude evidence quality is low and outcomes versus surgical fundoplication remain uncertain.

Accordingly, Stretta is considered unproven and may be denied if presented as an established alternative to standard therapies absent compelling objective documentation and longer‑term comparative evidence.

Endoscopic plication, suturing, and other minimally invasive endoluminal procedures have shown inconsistent long‑term effectiveness in many studies; early symptomatic improvements often diminish over several years and objective measures of reflux (pH/manometry) do not consistently improve.

Because of these limitations in durability and variable methodology across studies, such procedures are considered unproven for broad clinical application and are not supported as routine alternatives to established surgical or medical management.

Some devices, including the LINX MSA system, have promising short‑term results but the evidence is insufficient to conclusively establish long‑term effectiveness and safety across broader patient populations. Systematic reviews and guideline evaluations highlight limited follow‑up duration and the need for larger randomized controlled trials with long‑term outcomes to fully define benefits and risks.

These evidence uncertainties mean that certain device‑based approaches may be considered investigational or selectively covered pending adequate data on durability and comparative effectiveness.

Professional society guidance (ACG) does not recommend radiofrequency energy (Stretta) as a routine anti‑reflux procedure because of inconsistent efficacy data. The ACG guidance gives a conditional recommendation against Stretta, reflecting low quality evidence and uncertainty about longer‑term outcomes.

This guideline‑level caution supports the policy position that Stretta remains unproven and should be approached with caution, requiring strong objective documentation if considered for an individual patient.

The excerpted sections do not enumerate every specific scenario classified as 'not medically necessary.' Reviewers and providers must reference the full policy and applicable plan terms for definitive determinations of not medically necessary (NMN) conditions and coverage decisions.

Applicable Procedure and Regulatory Codes

Applicable procedure CPT codesCPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.

1–10 of 14

1/2

Device and procedure mentions (no explicit billing codes listed in this excerpt)mixed

No codes listed

Procedures discussed (TIF, MSA/LINX, polymer injections)mixed

affected codes

Placeholder — specific CPT/HCPCS codes not listed in this extract

Regulatory identifiersmixed

P100049

FDA PMA number for LINX Reflux Management System (informational)

Regulatory identifiersmixed

K233240

FDA 510(k) number for GERDx-System (informational)

FDA device clearance typesmixed

510(k)

Clearance pathway for EsophyX2, MUSE, Stretta, EndoCinch, NDO Surgical systems (informational)

Applicable CPT Codes (added)CPTCovered

43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64595	Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array.

Clinical success definition (study)

Study clinical success definitionClinical success defined as ≥50% improvement in GERD‑HRQL total score AND discontinuation of PPI medication.

Source study exampleUsed as the success endpoint in long-term LINX cohort (Ferrari et al.), assessing symptom improvement and PPI discontinuation.

Measurement instrumentGERD‑Health Related Quality of Life (GERD‑HRQL) questionnaire was the validated symptom instrument referenced.

Prior Authorization, Documentation, and Step Therapy Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for device-based or procedural interventions covered by this policy. Providers should submit clinical records documenting the member meets clinical criteria and plan/contract terms prior to scheduling procedures.

Applies to procedures such as GES implantation, POEM, G-POEM, pyloroplasty, TIF, MSA, and other device implantations listed in policy CPT/HCPCS sections.
Prior authorization is implied for procedures when procedure codes listed in the policy are submitted; submit requisite documentation as listed below.

Prior Authorization

Prior Authorization Required for TIF and MSA

Prior authorization is required specifically for Transoral Incisionless Fundoplication (TIF) and Magnetic Sphincter Augmentation (MSA). Requests must document prior medical therapy and objective diagnostic testing consistent with guideline- and trial-based inclusion criteria.

Document at minimum: chronic PPI use history (duration and dose), objective abnormal ambulatory pH testing or DeMeester score, endoscopic evaluation (esophagitis, hiatal hernia size), and esophageal manometry when indicated.

Clinical Background and Evidence Summary

Core administrative changes in the recent revision include an operational title change, removal of Louisiana‑specific language, an updated coverage rationale noting GES as proven and medically necessary, and the addition of several CPT codes (43647, 43648, 43659, 43881, 43882, 64590, 64595) to the applicable code list.

Definitions of Conditions and Procedures

Achalasia — definition

DefinitionA primary esophageal motor disorder of unknown etiology characterized by impaired relaxation of the esophagogastric junction (EGJ) and loss of organized peristalsis.

Typical diagnostic contextDiagnosis and classification guided by esophageal manometry and clinical presentation.

Related proceduresPOEM is an established therapeutic option for achalasia per guidance and trials.

Diffuse Esophageal Spasm — definition

DefinitionA rare esophageal motility disorder characterized by simultaneous, uncoordinated, or rapidly propagated contractions of normal amplitude, typically accompanied by dysphagia.

Clinical featuresPatients commonly present with chest pain and dysphagia due to uncoordinated esophageal contractions.

Policy Updates and Revision History

2026-06-01policy_update

Policy title and references updated; operational renaming and minor administrative edits recorded in Policy History.

2026-04-01effective_date

Policy effective date recorded for the revised coverage criteria and coding updates.

2026-04-01coverage_changeLatest

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases

Policy CodePolicy CS079.T

Change TypeMaterial and non-material updates (GES addedCPT codes expanded)

Effective DateApr 1, 2026

Next Review DateN/A

SourceLink

On This Page

diagnosis of achalasia with documented symptoms; prior therapies as indicated

Supported by randomized trial and multiple society reviews.

Z-POEM for Zenker's diverticulum: Z-POEM may be an alternative to flexible endoscopic septotomy with similar short-term clinical success in expert centers, but long-term comparative effectiveness and durability are uncertain.symptomatic Zenker's diverticulum

Evidence limited; further prospective long-term studies needed.

Stretta coverage considerations: Stretta (radiofrequency) for GERD has inconsistent evidence: some RCTs and systematic reviews show symptom improvement but substantial uncertainty exists about comparative effectiveness versus fundoplication and sham; at least one double-blind RCT did not demonstrate efficacy versus sham, therefore Stretta remains unproven and should be considered experimental or covered selectively with robust documentation.refractory GERD despite optimized PPI therapy

Recommend caution and potential denial absent strong objective documentation (pH, DeMeester, GERD-HRQL).

Supported by AGA, SAGES, and ACG guidance and RCT/observational evidence; consider prior authorization for G-POEM.

For MSA candidacy, document persistent moderate-to-severe regurgitation despite optimized PPI therapy and eligibility per device labeling (e.g., hiatal hernia < 3 cm, absence of advanced esophagitis or Barrett's).

Prior Authorization

Prior Authorization Recommended for Device Implantation

Prior authorization is recommended for implantation of FDA-cleared or approved devices and other device-based procedures to ensure appropriate patient selection and documentation of device-specific indications.

Include device make/model and FDA approval/HDE/PMA status (e.g., Enterra HDE; LINX PMA).
Describe operator training/credentials if using specialized devices or performing advanced endoscopic procedures.

Denial Risk

Denial Risk: GES for Non-refractory Gastroparesis

Gastric electrical stimulation (GES) may be denied if used for non-refractory gastroparesis or without documentation of failure of standard/conservative therapies. Ensure documentation demonstrates medically refractory symptoms prior to GES consideration.

Document failed trials of dietary modification, prokinetics, antiemetics, nutritional support, and other standard therapies.
Refer to FDA HDE labeling for Enterra and ensure member meets labeled indications (e.g., drug-refractory nausea and vomiting secondary to diabetic or idiopathic gastroparesis).

Denial Risk

Denial Risk: Insufficient Long-term Comparative Evidence

Insufficient long-term comparative evidence versus established surgical or medical therapies may lead to denial for procedures where long-term durability is unproven (e.g., some endoscopic anti-reflux therapies, TIF, and emerging interventions).

Coverage decisions will consider the quality and duration of evidence comparing the procedure to fundoplication, long-term PPI therapy, or other standard treatments.
Lack of long-term outcomes or comparative trials supporting durable benefit is a basis for noncoverage or additional documentation requests.

Documentation Required

Required Clinical Documentation

Medical records and clinical documentation are required to support medical necessity for prior authorization and coverage determinations. Incomplete documentation may result in denial of coverage.

Required elements include the diagnosis, prior failed or intolerant conservative therapies, objective diagnostic testing results, symptom severity scores, and duration of symptoms.
Reviewers will reference federal, state, or contractual benefit plan terms in determining coverage; plan terms govern in the event of conflict.

Documentation Required